Rigel Pharmaceuticals Inc. (NASDAQ:RIGL)’s traded shares stood at 4.04 million during the last session, with the company’s beta value hitting 0.73. At the close of trading, the stock’s price was $1.68, to imply an increase of 4.35% or $0.07 in intraday trading. The RIGL share’s 52-week high remains $3.52, putting it -109.52% down since that peak but still an impressive 61.9% since price per share fell to its 52-week low of $0.64. The company has a valuation of $307.81M, with an average of 6.42 million shares in intraday trading volume over the past 10 days and average of 3.52 million shares over the past 3 months.

Analysts have given a consensus recommendation of an Overweight for Rigel Pharmaceuticals Inc. (RIGL), translating to a mean rating of 2.40. Of 7 analyst(s) looking at the stock, 0 analyst(s) give RIGL a Sell rating. 0 of those analysts rate the stock as Overweight while 4 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.11.

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) trade information

After registering a 4.35% upside in the last session, Rigel Pharmaceuticals Inc. (RIGL) has traded red over the past five days. The stock hit a weekly high of 1.8300 this Wednesday, 03/15/23, jumping 4.35% in its intraday price action. The 5-day price performance for the stock is -6.15%, and 3.70% over 30 days. With these gigs, the year-to-date price performance is 12.00%. Short interest in Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) saw shorts transact 5.64 million shares and set a 1.5 days time to cover.

Analysts on Wall Street suggest a consensus price target of $3.99, implying an increase of 57.89% to the stock’s current value. The extremes give us $1.20 and $15.00 for target low and target high price respectively. As such, RIGL has been trading -792.86% off suggested target high and 28.57% from its likely low.

Rigel Pharmaceuticals Inc. (RIGL) estimates and forecasts

Looking at statistics comparing Rigel Pharmaceuticals Inc. share performance against respective industry, we note that the company has outperformed competitors. Rigel Pharmaceuticals Inc. (RIGL) shares are 29.23% up over the last 6 months, with its year-to-date growth rate higher than industry average at 11.76% against 11.00%. Revenue is forecast to grow 15.40% this quarter before jumping 43.80% for the next one. The rating firms project that company’s revenue will shrink -32.00% compared to the previous financial year.

Revenue forecast for the current quarter as set by 5 analysts is $27.97 million. Meanwhile, for the quarter ending Mar 2023, a total of 2 analyst(s) estimate revenue growth to $22.86 million.Earnings reports from the last fiscal year show that sales brought in $20.41 million and $16.73 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 37.00% before jumping 36.60% in the following quarter.

RIGL Dividends

Rigel Pharmaceuticals Inc. has its next earnings report out between May 01 and May 05. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Rigel Pharmaceuticals Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL)’s Major holders

Rigel Pharmaceuticals Inc. insiders hold 1.44% of total outstanding shares, with institutional holders owning 74.94% of the shares at 76.04% float percentage. In total, 74.94% institutions holds shares in the company, led by Blackrock Inc. As of Sep 29, 2022, the company held over 16.18 million shares (or 9.36% of shares), all amounting to roughly $19.09 million.

The next major institution holding the largest number of shares is FMR, LLC with 15.49 million shares, or about 8.96% of shares outstanding. As of the market price on Sep 29, 2022, these shares were worth $18.27 million.

We also have Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Rigel Pharmaceuticals Inc. (RIGL) shares. Going by data provided on Sep 29, 2022, Vanguard Total Stock Market Index Fund holds roughly 5.16 million shares. This is just over 2.98% of the total shares, with a market valuation of $6.08 million. Data from the same date shows that the other fund manager holds a little less at 3.85 million, or 2.23% of the shares, all valued at about 5.77 million.